Related by context. All words. (Click for frequent words.) 72 recurrent glioblastoma multiforme 71 riociguat 70 relapsed MM 70 MAGE A3 ASCI 70 CYT# potent vascular disrupting 69 YONDELIS 69 recurrent malignant glioma 69 gastrointestinal stromal tumors GIST 69 treatment naive genotype 69 MGd 69 Oral Fingolimod 69 OHR/AVR# 68 noninfectious uveitis 68 Dupuytren Disease 68 treatment naïve genotype 68 kidney urologic 68 Malignant Glioma 68 fosbretabulin 68 Cutaneous T 68 Bezielle 68 HCV SPRINT 68 invasive candidiasis 67 blinded randomized placebo controlled 67 Traficet EN 67 IMPACT DCM 67 investigational monoclonal antibody 67 HIV HCV coinfected 67 Castration Resistant Prostate Cancer 67 Hormone Refractory Prostate Cancer 67 PSMA ADC 67 CIMZIA TM certolizumab pegol 67 SNT-MC#/idebenone 67 complement inhibitor eculizumab 67 samalizumab 67 AA Amyloidosis 67 trastuzumab Herceptin ® 67 superficial bladder cancer 67 forodesine 67 Acute myeloid leukemia 67 dose escalation phase 67 metastatic neuroendocrine tumors 67 Virulizin ® 67 Metastatic Melanoma 67 relapsing multiple sclerosis 67 Valopicitabine 67 invasive aspergillosis 67 CCR5 tropic HIV 67 budesonide foam 67 primary immunodeficiency PI 66 relapsing remitting MS RRMS 66 CIMZIA ™ 66 Blinatumomab 66 metastatic GIST 66 Aflibercept 66 Chronic Myeloid Leukemia 66 atypical Hemolytic Uremic Syndrome 66 Acute Ischemic Stroke 66 Glioblastoma Multiforme 66 Azedra 66 Sipuleucel T 66 Advanced Melanoma 66 GAMMAGARD 66 Ataluren 66 Ophena TM 66 Hepatocellular Carcinoma HCC 66 Phase 2b Clinical Trial 66 GVAX Pancreas Vaccine 66 NeuroStar TMS Therapy 66 INSPIRE Trial Phase III 66 Ozarelix 66 GOUT 66 See CLINICAL PHARMACOLOGY 66 CCX# 66 Tumor Response 66 Advaxis Phase 66 metastatic colorectal 66 Leukemias 66 IMA# 66 Malignant Melanoma 66 eosinophilic asthma 66 VP# [004] 66 Bayer HealthCare Onyx Pharmaceuticals 66 Tyrosine Kinase Inhibitors 66 II Clinical Trial 66 Degarelix 66 aflibercept VEGF Trap 66 Enzastaurin 66 Phase #b/#a clinical 66 INFERGEN 66 velafermin 66 catheter occlusion 66 Hepatotoxicity 66 Soft Tissue Sarcoma 66 Phase III Pivotal 66 pelvic malignancies 66 rFVIIa 65 TORISEL 65 DEB# 65 masitinib 65 Rilonacept 65 ZOLINZA 65 Omacetaxine 65 EchoCRT 65 CIPN 65 Severe Primary IGFD 65 constipation OIC 65 CEQ# 65 de novo kidney transplant 65 mapatumumab 65 CHAMPION PCI 65 BEXXAR Therapeutic Regimen 65 Phase IIIb clinical 65 Methylnaltrexone 65 CCR5 mAb 65 radiolabeled TM# 65 dose escalation clinical 65 allogeneic HSCT 65 Eculizumab 65 HQK 65 Rheos System 65 rALLy clinical trial 65 cobiprostone 65 Sapacitabine 65 hepatitis C HCV 65 Severe Sepsis 65 CIMZIA TM 65 ChronVac C R 65 rilonacept 65 Myelodysplastic Syndrome MDS 65 Relapsing Remitting Multiple Sclerosis 65 Non inferiority 65 alfa 2a 65 steroid refractory 65 phase IIb clinical 65 Randomized Phase 65 hepatitis C genotype 65 either acutely decompensated 65 Acute Decompensated Heart Failure 65 Juvenile Idiopathic Arthritis 65 chronic myeloid 65 BR.# 65 keloid scarring 65 ZACTIMA 65 Teriflunomide 65 refractory gout 65 Gleevec resistant 65 relapsed AML 65 Aplidin R 65 Cardiotoxicity 65 CTAP# Capsules 65 Chronic HCV 65 Dacogen injection 65 HCV RESPOND 2 65 Critical Limb Ischemia CLI 65 docetaxel Taxotere ® 65 Heterozygous Familial Hypercholesterolemia 65 overactive bladder syndrome 65 #I TM# 65 HuMax EGFr 65 Investigational Treatment 65 Cell Lymphoma 65 assessing T DM1 65 Pivotal Phase III 65 cutaneous squamous cell carcinoma 65 Chronic lymphocytic leukemia 65 MYCAMINE 65 APTIVUS r 65 Refractory Angina 65 Pemetrexed 65 demonstrated antitumor activity 65 Diabetic Macular Edema 65 Follicular Lymphoma 65 Hematologic 65 refractory prostate cancer 65 refractory cutaneous T 65 myelofibrosis polycythemia vera 65 evaluating mipomersen 65 Pooled Analysis 65 Naive Patients 65 MenACWY 64 EXJADE 64 pharmacokinetic PK study 64 ToGA 64 Neovascular AMD 64 null responder HCV 64 Oncophage vaccination 64 Vicinium TM 64 Complicated Skin 64 Golimumab 64 Metastatic Colorectal Cancer 64 follicular lymphomas 64 LEUKINE 64 Antitumor Activity 64 sorafenib tablets 64 dasatinib Sprycel ® 64 Pegylated Interferon 64 novel VDA molecule 64 PRoFESS 64 Phase 2a trial 64 Meningiomas 64 K ras mutations 64 Decitabine 64 Vascugel 64 Bronchiectasis 64 osteoporotic vertebral compression fractures 64 recurrent NSCLC 64 oral prodrug 64 PROSTVAC VF 64 Epratuzumab 64 Metastatic Prostate Cancer 64 Hepatocellular Carcinoma 64 Cethromycin 64 Relapsing Multiple Sclerosis 64 brivaracetam 64 neutropenic patients 64 rALLy 64 ALN TTR 64 biliary tract cancer 64 oral FTY# 64 Toxicities 64 VFEND 64 Sudhir Agrawal D.Phil 64 visilizumab 64 Respiratory Syncytial Virus 64 Myelofibrosis 64 icatibant 64 HDL Selective Delipidation 64 ACTEMRA TM 64 FluCAM arm 64 CRLX# 64 Prodarsan 64 davunetide intranasal AL 64 Adult Stem Cell Therapy 64 IRX 2 64 Myelodysplastic Syndromes 64 noscapine 64 castrate resistant prostate cancer 64 T1DM 64 non metastatic osteosarcoma 64 Thiovir 64 lucinactant 64 symptomatic BPH 64 acute humoral rejection 64 paclitaxel Taxol R 64 Alferon LDO 64 Alequel 64 Advanced Renal Cell 64 Romiplostim 64 Tyrosine Kinase Inhibitor 64 psoriatic arthritis PsA 64 LUX Lung 64 TransVax ™ 64 NP2 Enkephalin 64 Natalizumab 64 LUMINATE 64 acute PAO 64 phase IIb trial 64 oral JAK1 64 desvenlafaxine succinate 64 placebo controlled clinical 64 clevidipine 64 hypereosinophilic syndrome 64 EVIZON TM 64 Candida infection 64 Randomized Phase II 64 Twinrix 64 Cerebril TM 64 PEGylated interferon beta 1a 64 PEG SN# 64 TTF Therapy 64 p# biomarker 64 VIR# 64 chronic GVHD 64 STRIDE PD 64 acute HAE attacks 64 esophageal candidiasis 64 acute GvHD 64 SPRYCEL ® 64 stage IIIb IV 64 TACI Ig 64 NOMID 64 recurrent GBM 64 myelodysplastic myeloproliferative diseases 64 efalizumab 64 canakinumab 64 Androxal TM 64 denileukin diftitox 64 HCD# [002] 63 phase IIa clinical 63 dual endothelin receptor antagonist 63 Pivotal Phase 63 Kepivance 63 Aliskiren 63 nonmetastatic 63 hyperphenylalaninemia HPA due 63 Talabostat 63 recurrent glioblastoma multiforme GBM 63 Dapagliflozin 63 induce remission 63 MKC# MT 63 ganetespib 63 XL# SAR# 63 severe oral mucositis 63 metastatic malignant 63 Safinamide 63 cilengitide 63 Glioma 63 palifermin 63 elacytarabine 63 cisplatin chemotherapy 63 Phase III Clinical Trial 63 Phase 2b Trial 63 PegIFN RBV 63 chronic myocardial ischemia 63 Exelixis XL# 63 Enzyme Replacement Therapy 63 Acute Myocardial Infarction 63 randomized Phase IIb 63 ELACYT 63 vidofludimus 63 Tarceva TM 63 Dasatinib 63 SNT MC# 63 BRIM2 63 CMV infection 63 Prolongs Survival 63 Adjuvant chemotherapy 63 papillary renal cell carcinoma 63 diarrhea predominant irritable 63 Vandetanib 63 colesevelam HCl 63 Relapsed Multiple Myeloma 63 polycythemia vera essential thrombocythemia 63 Forodesine HCl 63 R roscovitine 63 candidemia 63 anterior uveitis 63 cytomegalovirus infection 63 cisplatin gemcitabine 63 Rheumatoid Arthritis RA 63 MAGE A3 63 TYZEKA 63 NAVISTAR R 63 Hedgehog Pathway Inhibitor 63 stage IIIB 63 omega interferon 63 HDAC Inhibitor 63 Pemphigus 63 Hsp# Inhibitor 63 BARACLUDE ® 63 Alocrest 63 Acute Radiation Syndrome ARS 63 Raptiva r 63 cat dander allergy 63 Bazedoxifene 63 QLT# 63 AEG# 63 Glypromate 63 C1 INH deficiency 63 REMINYL ® 63 PREZISTA r 63 minimally symptomatic 63 CALGB # [002] 63 DDP# 63 lymphoma CTCL 63 neuroblastoma tumors 63 erlotinib Tarceva ® 63 evaluating tivozanib 63 Solid Tumors 63 alvespimycin 63 randomized multicenter trial 63 orally inhaled migraine 63 moderate renal impairment 63 Phase Ib II 63 Accelerated Partial Breast Irradiation 63 pancreatic adenocarcinoma 63 Dupuytren Contracture 63 CMV reactivation 63 Nebulized 63 Combination REOLYSIN R 63 symptomatic hyponatremia 63 Squalamine 63 Severe Asthma 63 oral ridaforolimus 63 cutaneous T 63 pancreatic carcinoma 63 Lenocta 63 HER2 positive metastatic breast 63 MYDICAR ® 63 Myelodysplastic Syndrome 63 recurrent glioblastoma 63 HBeAg negative 63 Haptoglobin 63 GSK# [001] 63 AA amyloidosis 63 PRADAXA 63 glioblastoma multiforme GBM 63 indolent follicular non 63 colorectal liver metastases 63 Nilotinib 63 Prospective Randomized 63 Antiviral Activity 63 Randomized Double blind 63 CANCIDAS 63 ADAGIO study 63 Treatment Naive Patients 63 glucocorticoid induced osteoporosis 63 clinical pharmacology studies 63 ALISTA 63 leukemia AML 63 HuLuc# 63 prostate cancer CRPC 63 EOquin TM 63 urothelial cancer 63 metastatic gastric 63 Microplasmin 63 HCV Protease Inhibitor 63 ST Elevation Myocardial 63 IL# PE#QQR 63 Romidepsin 63 Velcade bortezomib 63 Afatinib 63 myoblast therapy 63 intravenous methylnaltrexone 63 tanespimycin 63 OncoVEX GM CSF 63 hA# 63 Major Depressive Disorder MDD 63 INCB# [001] 63 trastuzumab DM1 T DM1 63 RSD# oral 63 Exherin TM 63 TNF antagonist 63 ribavirin RBV 63 pain palliation 63 recombinant PSMA vaccine 63 GW# [003] 63 metastatic malignant melanoma 63 LHRH antagonists 63 verteporfin 63 Decompensated Heart Failure 63 galiximab 63 polycythemia vera PV 63 chronic eosinophilic leukemia 63 myeloproliferative diseases 63 pulmonary metastasis 63 Pivotal Trial 63 Lupus Nephritis 63 VitiGam 63 solid organ transplantation 63 acadesine 63 Aggrastat ® tirofiban hydrochloride 63 Tyrima 63 post herpetic neuralgia PHN 63 adult chronic ITP 63 malignant ascites 63 Vascugel ® 63 Epidermal Growth Factor Receptor 63 paclitaxel poliglumex 63 gadobutrol 63 Temsirolimus 63 hepatocellular cancer 63 Fludara ® 63 Renal Cell Carcinoma 63 Archexin 63 Tesetaxel 63 refractory CLL 63 anti CD3 antibody 62 ABSSSI 62 CMV disease 62 vWD 62 Symadex 62 Telbivudine 62 ALN VSP Phase 62 Gliadel Wafer 62 CBLC# 62 sorafenib Nexavar 62 evaluable subjects 62 systemic RNAi therapeutic 62 heavily pretreated 62 Melphalan 62 gastric adenocarcinoma 62 Atypical Hemolytic Uremic Syndrome 62 Interferon Beta 62 Newly Diagnosed Multiple Myeloma 62 NATRECOR R 62 metastatic CRC 62 Anthracycline 62 ABSORB trial 62 oropharyngeal candidiasis 62 JVRS 62 Personalized Immunotherapy 62 dosing cohort 62 mCRC patients 62 ritonavir boosted 62 Catheter Ablation 62 Rigel R# 62 haematological malignancies 62 AGHD 62 NLX P# 62 decitabine 62 acute coronary syndromes ACS 62 Meets Primary Endpoint 62 biologic DMARD 62 delayed CINV 62 pertuzumab 62 plasma kallikrein 62 G#DT 62 diabetic neuropathic pain 62 fallopian tube cancers 62 tigecycline 62 Metastatic breast cancer 62 Antitumor activity 62 Vaccine Adjuvant 62 Phase #b/#a trial 62 Phase 2b Study 62 seminoma 62 Bosutinib 62 Pivotal Clinical Trial 62 FOLOTYN ® 62 undergoing elective percutaneous 62 Mucositis 62 Triolex 62 toenail onychomycosis 62 R#/MEM # 62 Treating Chronic 62 pan HDAC inhibitor 62 Sym# 62 neoadjuvant treatment 62 Systemic Sclerosis 62 Metastatic Renal Cell Carcinoma 62 Myelodysplastic syndromes MDS 62 HCV Genotype 62 Cimzia ® certolizumab pegol 62 SCCHN 62 GRNCM1 62 FASLODEX 62 chronic periodontitis 62 Truvada tablets 62 OPT CHF 62 Fibrillex TM 62 solithromycin 62 immunocompetent 62 Diabetic Macular Edema DME 62 Surgical resection 62 indibulin 62 pomalidomide 62 CDAD Clostridium difficile 62 corticosteroid therapy 62 PREZISTA ritonavir 62 CHARM Added 62 ISF# 62 ziconotide 62 APTIVUS R 62 Hypotension 62 inhibitor RG# 62 rituximab refractory 62 hematologic disorders 62 Aplidin 62 PrevOnco ™ 62 mycophenolate mofetil MMF 62 Chronic Myelogenous Leukemia CML 62 evaluating Prochymal 62 neratinib 62 Poly ICLC 62 pulmonary hypertension PH 62 IMC #B 62 allogeneic hematopoietic stem cell 62 mRCC 62 antiretroviral naïve 62 protease inhibitor PI 62 refractory angina 62 Patients Treated With 62 SSc 62 ImmunoVEX HSV2 62 huN# DM1 62 receptor tyrosine kinase inhibitor 62 HER2 overexpression 62 KRN# 62 briakinumab 62 Quinamed 62 decompensated liver disease 62 acute myeloid 62 PCNSL 62 Prostate AdenoCarcinoma Treatment 62 erythropoietic 62 Phase 1b clinical trials 62 hereditary deficiency 62 plasma kallikrein inhibitor 62 recurrent metastatic 62 Unresectable 62 CLARITY study 62 combination antiretroviral therapy 62 antiretroviral naive 62 Anti VEGF 62 TMS Therapy 62 Vidofludimus 62 TNF alpha antagonist 62 relapsed refractory multiple myeloma 62 SCIg 62 TLK# 62 mecarbil 62 ISTODAX 62 chronic ITP patients 62 Placebo Controlled Study 62 RhuDex 62 PRTX 62 APTIVUS ritonavir 62 IV NSCLC 62 liposomal amphotericin B 62 Acute Myeloid Leukaemia AML 62 synthetic retinoid 62 HoFH 62 EVIZON 62 INTEGRILIN R 62 systemic fungal infections 62 intravesical infusion therapy 62 BENICAR HCT 62 null responder 62 Phase Ib clinical 62 ADVEXIN therapy 62 vWF 62 mycophenolate mofetil 62 Ranolazine 62 PROCHYMAL 62 selective modulator 62 Altastaph 62 phase IIb III 62 BRIM3 62 unresectable stage 62 leukemia ALL 62 calcineurin inhibitor 62 lomitapide 62 Acute Heart Failure 62 lead Aganocide compound 62 HBeAg + 62 mycosis fungoides 62 PORxin TM platforms 62 opioid induced constipation OIC 62 familial amyloidotic polyneuropathy FAP 62 recurrent metastatic ovarian cancer 62 GRN# 62 Chronic Lymphocytic Leukemia CLL 62 RCW breast cancer 62 Delcath Phase III 62 Chronic Prostatitis 62 metastatic RCC 62 trial evaluating PRX# 62 metastatic uveal melanoma 62 immunomodulator 62 Valortim R 62 Polyneuropathy 62 NATRECOR ® 62 Pharmacokinetics PK 62 HERCEPTIN 62 TG MV 62 Lubiprostone 62 Pimavanserin 62 underwent resection 62 Initiate Phase 62 AGILECT R 62 Mitomycin C 62 Double Blind Placebo 62 Elotuzumab 62 oral rivaroxaban 62 hepatorenal syndrome 62 medically refractory 62 nephrotoxicity 62 asymptomatic metastatic 62 IIa clinical 62 ENMD # 62 INVEGA ® 62 Clostridium difficile Infection 62 Aethlon Hemopurifier R 62 Ischemic 62 Dacogen decitabine 62 Liprotamase 62 Treatment Shows Promise 62 Imprime PGG 62 imatinib therapy 62 standard chemotherapy regimen 62 Squamous 62 iobenguane 62 basiliximab 62 azilsartan medoxomil 62 multicenter randomized placebo controlled 62 Heart Transplant Recipients 62 somatostatin analog 62 atopic asthma 62 ORMD 62 Tanespimycin 62 Phase Ib IIa 62 Phase Ib Clinical Trial 62 mg/m2 dose 62 nucleotide analog 62 Hypoactive Sexual Desire Disorder 62 viral kinetics 62 CR# vcMMAE 62 included exfoliative dermatitis 62 Universal Flu Vaccine 62 quadrivalent HPV vaccine 62 Phase 2a Clinical Trial 62 Patients Receiving 62 SYN# 62 venous thromboembolic events 62 Systemic lupus erythematosus SLE 62 Basal Cell 62 Daclizumab 62 nucleoside analog 62 Edge STudy 62 ARIXTRA 62 refractory metastatic 62 Xelox 62 Val HeFT 62 recurrent genital herpes 62 Chemophase 62 osteoporotic compression fractures 62 BRAF V#E 62 medically inoperable 62 Plasmin 62 Phase Ib study 62 neovascular diseases 62 pediatric malignancies 62 rindopepimut 62 hepatitis C viral infection 62 chronic thromboembolic pulmonary 62 Adalimumab 62 opioid naive 62 including eniluracil ADH 62 retinal vein occlusion 62 thoracoscopic lobectomy 62 CAMMS# 62 Kinoid 62 huC# DM4 62 interferon gamma 1b 62 Ribavirin causes 62 Motesanib 62 KETEK 62 membranous nephropathy 62 anemia thrombocytopenia 62 Vacc 4x 61 pemphigus vulgaris 61 IIa trials 61 Progressive Multifocal Leukoencephalopathy 61 carcinoid tumors 61 monoclonal antibody conjugated 61 chemoradiation therapy 61 metastatic androgen independent 61 Kit CD# positive 61 Apaziquone 61 Phase 1b trial 61 esophageal gastric 61 HIV coinfected 61 #th Annual Interscience 61 Angiox R 61 TMC# C# 61 INCB# [003] 61 PROSTVAC ® 61 DCVax R 61 Demonstrates Efficacy 61 constipation predominant irritable bowel 61 cholangiocarcinoma 61 BrachySil TM 61 Bipolar Mania 61 oral picoplatin 61 antibody MAb 61 Adjuvant Treatment 61 Relapsed Refractory 61 #F FDG PET 61 RE MODEL 61 Cardiac Resynchronization 61 Late Breaker 61 PhG alpha 1 61 Nitazoxanide 61 Aryplase 61 MEND CABG 61 ROTARIX 61 relapsed leukemia 61 Acute Stroke 61 acute peripheral arterial 61 mixed hyperlipidemia 61 Multicenter Randomized 61 Lymphocytic 61 phase Ib 61 Carotid Endarterectomy 61 mutated KRAS gene 61 ThermoDox ® clinical 61 Mycophenolate Mofetil 61 Paroxysmal Nocturnal Hemoglobinuria PNH 61 posterior uveitis 61 Tectin TM 61 ENESTnd 61 HCV infected 61 HGS ETR1 61 mg/m2 cohort 61 hematopoietic cancers 61 TTR amyloidosis 61 OvaRex ® MAb 61 ATTR 61 LibiGel ® 61 Subarachnoid hemorrhage 61 antiangiogenic therapy 61 LHRH receptor positive 61 ara C 61 Improves Outcomes 61 Evoltra ® 61 Infusion reactions 61 serum antibody 61 COSIRA trial 61 metastatic renal cell carcinoma 61 opioid bowel dysfunction 61 EGFR HER2 61 DermaVir Patch 61 transthyretin amyloidosis 61 pyridostigmine 61 KRAS mutations occur 61 flavopiridol 61 malignant pleural mesothelioma 61 IFN alfa 61 Trastuzumab 61 thorough QT 61 colorectal carcinoma 61 Phase III Clinical Trials 61 Immunotherapeutic 61 imatinib resistant 61 venous stasis ulcers 61 Inhaled nitric oxide 61 dirucotide MBP# 61 ALN HPN 61 Diabetic Neuropathy 61 idiopathic thrombocytopenic purpura 61 Amgen Neulasta R 61 AZILECT ® 61 ORENCIA ® 61 peginterferon alfa 61 immunocompetent patients 61 CINQUIL 61 Placebo Controlled Trial 61 acute leukemias 61 S. aureus bloodstream infections 61 HSCT 61 cMET 61 heparin induced thrombocytopenia 61 HCV NS5B polymerase 61 multicenter clinical 61 OncoVex 61 LymphoStat B TM 61 simplex virus 61 refractory chronic myeloid 61 EGFR TKI 61 Aethlon Hemopurifier ® 61 registrational Phase 61 RhD positive 61 oral talactoferrin 61 Peginterferon 61 refractory anaplastic astrocytoma 61 ximelagatran 61 Advanced Heart Failure 61 Pertuzumab 61 relapsed multiple myeloma 61 lenalidomide Revlimid R 61 tramiprosate Alzhemed TM 61 thalidomide Thalomid 61 metastatic bladder 61 relapsed ALL 61 LibiGel Phase III 61 postexposure prophylaxis 61 R Saizen R 61 refractory indolent non 61 AIR2 Trial 61 OMNARIS HFA 61 ovarian carcinoma 61 pheochromocytoma 61 lymphoid malignancies 61 number NCT# ClinicalTrials.gov 61 vapreotide acetate 61 orally administered inhibitor 61 unresectable tumors 61 Diamyd r 61 Acute Myelogenous Leukemia AML 61 ancrod 61 CERVARIX 61 lumbar spinal stenosis LSS 61 EDEMA3 61 myocardial infarction ventricular fibrillation 61 curative resection 61 autoantibody positive 61 PXD# 61 Warfarin Coumadin 61 CRVO 61 ß blockers 61 abacavir Ziagen 61 Fulvestrant 61 lumiliximab 61 HBV vaccine 61 transarterial 61 PRECiSE 61 intravascular hemolysis 61 intra articular injection 61 basal cell carcinoma BCC 61 alefacept 61 Acute Myelogenous Leukemia 61 PNP inhibitor 61 LungSign TM 61 Hydroxyurea 61 grade cervical intraepithelial 61 epithelial tumors 61 Zemplar Capsules 61 metastatic hormone refractory 61 allogeneic bone marrow 61 sunitinib Sutent ® 61 ILLUMINATE 61 Chronic Lymphocytic Leukemia 61 LHON 61 ASPIRE HIGHER 61 PROSTVAC TM 61 DOXIL 61 phase IIb study 61 Cachexia 61 Systemic Lupus Erythematosus SLE 61 Diffuse Large B 61 HBV infections 61 Xcytrin R 61 Antiviral Therapy 61 elotuzumab 61 Cervista HPV HR 61 Gastrointestinal Stromal Tumors 61 Autoimmune Diseases 61 neovascular form 61 CML CP 61 chronic opioid 61 omacetaxine mepesuccinate 61 Deforolimus 61 Hepatitis C Antiviral 61 carcinoma HCC 61 Waldenstrom macroglobulinemia 61 Chronic Sinusitis 61 castration resistant prostate cancer 61 immunosuppressed patients 61 Inhalation Solution 61 SPRIX ® 61 TEMODAL 61 Pivotal Study 61 Pulmonary Arterial Hypertension 61 TRO# 61 oral methylnaltrexone 61 imatinib resistance 61 genotype 1b 61 Phase 1b 61 Randomized Double Blind 61 Pafuramidine 61 Ophena 61 SUTENT ® 61 latent tuberculosis infection 61 Overactive Bladder OAB 61 acyclovir Lauriad R 61 ADVANCE PD 61 Venous thromboembolism 61 immunosuppressive regimens 61 squamous cell lung cancer 61 transplantation HSCT 61 Dose Escalation 61 HIF PH inhibitors 61 Infusion Reactions Severe 61 Radioimmunotherapy 61 BCR ABL inhibitor 61 Efficacy Trial 61 infliximab Remicade 61 hypophosphatasia 61 HBeAg positive patients 61 Phase 1a clinical 61 herpes zoster shingles 61 Gamunex C 61 PI3K/Akt pathway inhibitor 61 TroVax ® 61 ataluren 61 dose melphalan 61 Preclinical Study 61 immunological diseases 61 severe hypersensitivity reactions 61 lexidronam injection 61 paroxysmal atrial fibrillation 61 VA# [002] 61 retinal vein occlusion induced 61 Opportunistic infections 61 CALGB # [001] 61 Bendamustine 61 atherothrombotic disease 61 Etanercept 61 Tolvaptan 61 NYHA Class II 61 immunomodulatory agents 61 Community Acquired Pneumonia 61 metastatic castration resistant 61 GERD migraine headaches 61 Progenitor Cells 61 5 HT6 receptor 61 mildly symptomatic 61 MVA MUC1 IL2